SCHEMBL20440779

SCHEMBL20440779

N#Cc1c(C(F)(F)F)nc2ccc(Oc3ccccc3)cc2c1N1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 3/20 0.47
▸ SCN4A P35499 1/20 0.47
▸ ABCC8 Q09428 1/20 0.46
▸ KCNJ11 Q14654 1/20 0.46
▸ LTA4H P09960 1/20 0.43
▸ ADRB2 P07550 1/20 0.41
▸ SLC34A1 Q06495 3/20 0.40
▸ SLC34A3 Q8N130 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40
▸ SCN7A Q01118 3/20 0.39
▸ KCNH2 Q12809 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NCOA1 Q15788 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20435731 0.76 ABCC8 (0.62) ABCC8KCNJ11SLC34A1LMNAPOLB
SCHEMBL20435738 0.75 ABCC8 (0.54) ABCC8KCNJ11LMNAPOLBHTT
SCHEMBL20435733 0.70 PIK3CA (0.51) ABCC8KCNJ11SLC34A1LMNAPOLB
SCHEMBL20435739 0.69 ABCC8 (0.42) ABCC8KCNJ11LTA4HPOLBSMN1; SMN2
SCHEMBL20435732 0.67 ABCC8 (0.48) ABCC8KCNJ11PDE10ALMNAPOLB
SCHEMBL6529865 0.67 PDE10A (0.50) ABCC8KCNJ11PDE10APOLBSMN1; SMN2
SCHEMBL2090089 0.63 ABCC8 (1.00) ABCC8KCNJ11LMNAPOLBHTT
SCHEMBL4671118 0.63 LTA4H (0.75) SCN9ASCN4ALTA4HHTTMAPT
SCHEMBL2156502 0.63 LTA4H (1.00) SCN9ASCN4ALTA4HADRB2ALDH1A1
SCHEMBL20975374 0.63 PDE10A (0.44) ADRB2PDE10ALMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 — — US disclosed
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans KCL THERAPEUTICS, INC. (US) 2022-05-10 — — US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 — — US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 — — US disclosed
WO-2019104199-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY REGEN BIOPHARMA INC. (US) 2019-05-31 — — WO disclosed
WO-2019104201-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS Zander Therapeutics, Inc. (US) 2019-05-31 — — WO disclosed
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals Zander Therapeutics, Inc. 2019-02-21 — — US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 SCN9A 3222/4885SCN4A 1996/4885ABCC8 1987/4885
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 SCN9A 3144/4885SCN4A 1800/4885ABCC8 2042/4885
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals NR4A2, NR2C2, NR0B2 SCN9A 3144/4885SCN4A 1800/4885ABCC8 2042/4885
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans NR4A2, NR2C2, NR0B2 SCN9A 3222/4885SCN4A 1996/4885ABCC8 1987/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 SCN9A 3385/4885SCN4A 1924/4885ABCC8 1939/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 SCN9A 3144/4885SCN4A 1800/4885ABCC8 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback